Lupus & antiphospholipid syndrome
The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study
Authors' conclusion
Belimumab shows promising clinical outcomes in the treatment on patients with both SLE and ITP.
Study context
- Population
- Female patients with both systemic lupus erythematosus (SLE) and immune thrombocytopenia (ITP) (mean age 34.3 ± 14.0 years, mean weight 58.7 ± 18.2 kg)all female
- Participants
- 10 patients
- Exposure
- Belimumab added to basic drug therapy, before vs after treatment
- Belimumabn = 10
- Outcome
- Overall response rate of thrombocytopenia after belimumab
- Follow-up
- After treatment
Main finding
As reported in the abstract
Overall response rate of thrombocytopenia
90%
Observational data: associations, not effects.
Further findings
Platelet count, lymphocyte count, erythrocyte count, hemoglobin, dsDNA, C3 and C4, before vs after treatment
- Significantly improved
- P < 0.05
SLE Disease Activity Index (SLEDAI), BILAG-2004 and Physician Global assessment (PGA) scores, before vs after treatment
- Significantly decreased
- P < 0.05
Safety
ALT, AST and serum creatinine, before vs after treatment
- No significant differences
- P > 0.05
Original publication
The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study. Lupus. Published 22 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →